Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00064829" target="_blank" >RIV/00216224:14110/11:00064829 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/978-1-4419-7207-1_13" target="_blank" >http://dx.doi.org/10.1007/978-1-4419-7207-1_13</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/978-1-4419-7207-1_13" target="_blank" >10.1007/978-1-4419-7207-1_13</a>

Result language
angličtina
Original language name
Angiotensin Converting Enzyme I/D Polymorphism and Cardiovascular Risk: Disclosed Story
Original language description
Rapid advances in molecular medicine have led to pronounced new developments in experimental and clinical cardiology. In the embrace of modern molecular biology and bridging the gap between the clinical and the genomic, cardiovascular medicine has seen major strides in the understanding of the molecular mechanisms that drive disease progression. The ability to rapidly identify candidate human genes for cardiovascular diseases lends itself to the development of diverse strategies for disease treatment and management. The wide variety of gene expressions proffers excellent targets for novel therapeutics. Gene therapy is steadily increasing in viability and represents a fascinating arena of research and clinical focus.
Czech name
—
Czech description
—

Project
<a href="/en/project/NS10206" target="_blank" >NS10206: Association of polymorphisms in genes for matrix metalloproteinases, their inhibitors, ACE and ACE2 with central pulse pressure in cardiovascular patients</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)